Estimasi Biaya Penyakit COVID-19 Rawat Inap di RSUP Dr. Sardjito Yogyakarta: Direct Medical Cost

Raymon Simanullang; Tri Murti Andayani; Chairun Wiedyaningsih

doi:10.22146/farmaseutik.v19i3.83529

Estimasi Biaya Penyakit COVID-19 Rawat Inap di RSUP Dr. Sardjito Yogyakarta: Direct Medical Cost

https://doi.org/10.22146/farmaseutik.v19i3.83529

Raymon Simanullang^(1*), Tri Murti Andayani⁽²⁾, Chairun Wiedyaningsih⁽³⁾

(1) Magister Manajemen Farmasi, Faculty of Pharmacy, Universitas Gadjah Mada
(2) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(3) Departemen Farmasetika, Fakultas Farmasi, Universitas Gadjah Mada
(*) Corresponding Author

Abstract

Kasus terkonfirmasi positif COVID-19 tercatat sejak 2019 hingga 2021 mengalami peningkatan yang cukup signifikan. Analisis biaya dengan cost of illness mampu mengidentifikasi dan mengukur biaya secara keseluruhan dari penanganan suatu penyakit. Tujuan penelitian ini untuk menganalisis total biaya medik langsung dan komponennya serta faktor-faktor yang mempengaruhi biaya pasien COVID-19 rawat inap di RSUP Dr. Sardjito Yogyakarta periode Juli-September 2021. Metode penelitian observasional analitik berdasarkan perspektif rumah sakit dengan rancangan penelitian cross sectional. Pengambilan data diambil secara retrospektif dari rekam medik, data rincian biaya pengobatan, dan berkas klaim pasien. Analisis data menggunakan analisis univariat, bivariat, dan multivariat. Hasil penelitian diperoleh jumlah pasien COVID-19 rawat inap sebanyak 99 sampel yang memenuhi kriteria inklusi, total biaya medik langsung Rp. 1.916.902.329 dengan rata-rata biaya per pasien Rp. 19.362.650, komponen biaya terbesar adalah biaya jasa pelayanan medis (53%) serta biaya obat dan BMHP (31,43%). Terdapat perbedaan total biaya medik langsung dari faktor jenis kelamin, lama rawat inap, dan kelas perawatan. Dapat disimpulkan bahwa ada pengurangan total biaya medik langsung yang dipengaruhi oleh variabel-variabel tersebut.

Keywords

Cost Analysis; COVID-19; Direct Medical Cost; Hospital Perspective; Inpatient

Full Text:

PDF

References

Agustina, Palu, B., Muchlis, N., 2020. Analisis Biaya Rill dan Tarif INA CBG’s Di Rumah Sakit Umum Bahagia Kota Makassar. J Muslim Community Health 1.

Andayani, T.M., 2013. Farmakoekonomi Prinsip dan Metodologi. Bursa Ilmu, Yogyakarta.

Bain, S.C., Czernichow, S., Bøgelund, M., Madsen, M.E., Yssing, C., McMillan, A.C., Hvid, C., Hettiarachchige, N., Panton, U.H., 2021. Costs of COVID-19 pandemic associated with diabetes in Europe: a health care cost model. Current Medical Research and Opinion 37, 27–36. https://doi.org/10.1080/03007995.2020.1862775

Bartsch, S.M., Ferguson, M.C., McKinnell, J.A., O’Shea, K.J., Wedlock, P.T., Siegmund, S.S., Lee, B.Y., 2020. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States: A simulation estimate of the direct medical costs and health care resource use associated with COVID-19 infections in the United States. Health Affairs 39, 927–935. https://doi.org/10.1377/hlthaff.2020.00426

Bootman, J.L., Townsend, R.J., McGhan, W.F. (Eds.), 2005. Principles of pharmacoeconomics, 3rd ed. Harvey Whitney Books Co, Cincinnati, OH.

BPJS Kesehatan, 2021. Penyebab Dispute Klaim COVID-19: Jalan Berliku Penyelesaian Dispute Klaim COVID-19, Seberapa Kuat Rumah Sakit Menanggung Beban Operasional? Badan Penyelenggara Jaminan Sosial Kesehatan, Jakarta.

Burhan, E., Susanto, A.D., Nasution, S.A., Ginanjar, E., Pitoyo, W., Susilo, A., Firdaus, I., Santoso, A., Arifa, D., Arif, S.K., Syam, F., Rasmin, M., Rengganis, I., Sukrisman, L., Wiyono, W.H., Isbaniah, F., Elhidsi, M., Aniwidyaningsih, W., Handayani, D., Sugiri, J.R., Wahyudi, E.R., Mulansari, N.A., Muchtar, F., Rumende, C.M., Soeroto, A.Y., Triyono, A., Katu, S., Agustina, P., Puspitorini, D., Prasetya, I., Musbah, T., Pulungan, A.B., Pudjiadi, A.H., Sjakti, A., Yanuarso, P.B., Alam, A., Kaswandani, N., Putri, N.D., Kadafi, K.T., Roeslaini, R.D., Sambo, M., 2020. Pedoman Tatalaksana COVID-19, 3rd ed. Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI).

CCDC, 2020. Covid-19. Chinese Centers for Disease Controls and Prevention, USA.

Cutler, D.M., Summers, L.H., 2020. The COVID-19 Pandemic and the $16 Trillion Virus. JAMA 324, 1495. https://doi.org/10.1001/jama.2020.19759

Dinkes Sleman, 2020. Dashboard Informasi Kabupaten Sleman COVID-19. Dinas Kesehatan Kabupaten Sleman, Yogyakarta.

Ejaz, H., Alsrhani, A., Zafar, A., Javed, H., Junaid, K., Abdalla, A.E., Abosalif, K.O.A., Ahmed, Z., Younas, S., 2020. COVID-19 and comorbidities: Deleterious impact on infected patients. Journal of Infection and Public Health 13, 1833–1839. https://doi.org/10.1016/j.jiph.2020.07.014

Goldstein, L.B., Samsa, G.P., Matchar, D.B., Horner, R.D., 2004. Charlson Index Comorbidity Adjustment for Ischemic Stroke Outcome Studies. Stroke 35, 1941–1945. https://doi.org/10.1161/01.STR.0000135225.80898.1c

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J., Cao, B., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395, 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

Jeck, J., Jakobs, F., Kron, A., Franz, J., Cornely, O.A., Kron, F., 2022. A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic “first wave” in a German tertiary care hospital. Infection 50, 191–201. https://doi.org/10.1007/s15010-021-01685-8

Menkes RI, 2021. Petunjuk Teknis Klaim Penggantian Biaya Pelayanan Pasien Corona Virus Disease 2019 (COVID-19) bagi Rumah Sakit Penyelenggara Pelayanan COVID-19. KMK No.HK.01.07/MENKES/4344/2021. Kementerian Kesehatan Republik Indonesia, Jakarta.

Menkes RI, 2020. Petunjuk Teknis Klaim Pengganti Biaya Perawatan Pasien Penyakit Infeksi Emerging Tertentu bagi Rumah Sakit yang Menyelenggarakan Pelayanan Coronavirus Diseases 2019 (COVID-19). KMK No. HK.01.07/MENKES/238/2020. Kementerian Kesehatan Republik Indonesia, Jakarta.

Paluseri, A., Oktaviani, R., Zulfahmidah, Z., Fajriansyah, F., 2021. Efektivitas Biaya Penggunaan Antibiotik Pasien COVID-19 di Rumah Sakit Tadjuddin Chalid Makassar. MF 17, 50. https://doi.org/10.32382/mf.v17i1.2050

Patria Jati, S., Budiyono, Tiyas Budiyanti, R., Suhartono, Ginandjar, P., Sriatmi, A., Nandini, N., 2020. Cost Estimates Related to COVID-19 Treatment in Indonesia: What Should be Concerned? E3S Web Conf. 202, 12012. https://doi.org/10.1051/e3sconf/202020212012

Rahmandani, A., Sarnianto, P., Anggriani, Y., Dermawan Purba, F., 2021. Analisis Efektivitas Biaya Penggunaan Obat Antivirus Oseltamivir dan Favipiravir pada Pasien Covid-19 Derajat Sedang di Rumah Sakit Sentra Medika Cisalak Depok. Maj. Farmasetika 6, 133. https://doi.org/10.24198/mfarmasetika.v6i0.36667

Rahmawati, C., Nurbaety, B., Qiyaam, N., Dini, S., Maftuhah, L., 2022. Cost of illness for COVID-19 inpatients in West Nusa Tenggara, Indonesia. Pharm Educ 22, 66–69. https://doi.org/10.46542/pe.2022.222.6669

Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K., Desai, P., Hosein, Z., Padda, I., Mangat, J., Altaf, M., 2020. Comorbidity and its Impact on Patients with COVID-19. SN Compr. Clin. Med. 2, 1069–1076. https://doi.org/10.1007/s42399-020-00363-4

Setyarini, Y., Suryawati, C., Arso, S.P., 2022. Analisis Pembiayaan COVID-19 di RSUP dr. Kariadi Semarang. Jurnal Manajemen Kesehatan Indonesia 10, 190–201. https://doi.org/10.14710/jmki.10.2.2022.190-201

Sugiyono, 2017. Metode Penelitian Kuantitatif, Kualitatif dan R&D. Alfabeta, Bandung.

Vermonte, P., 2020. Karakteristik dan Persebaran COVID-19 di Indonesia: Temuan Awal. CSIS Commentaries, Jakarta.

WHO, 2020. Coronavirus disease (COVID-19). World Health Organization.

Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., Zheng, M., Chen, L., Li, H., 2020. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B 10, 766–788. https://doi.org/10.1016/j.apsb.2020.02.008

Zhu, X., Ge, Y., Wu, T., Zhao, K., Chen, Y., Wu, B., Zhu, F., Zhu, B., Cui, L., 2020. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Research 285, 198005. https://doi.org/10.1016/j.virusres.2020.198005

DOI: https://doi.org/10.22146/farmaseutik.v19i3.83529